Nuwellis announces presentation of data on broad utility of Aquadex

Nuwellis (NUWE) announced the presentation of new real-world data from New York City’s Lenox Hill Hospital at the 2025 American Society of Nephrology, ASN, Kidney Week, reinforcing the versatility of Aquadex ultrafiltration therapy in patients with acute kidney injury, AKI, and complex fluid management needs. The retrospective analysis, titled “Diversifying Aquapheresis Applications in Critical Care: Nephrology-Led Institutional Experience,” reviewed 69 cases treated with Aquadex between 2018 and 2024. The study demonstrated effective and predictable fluid removal in patients with multiple underlying conditions-ranging from oliguric AKI and post-cardiac-surgery volume overload to pre-operative optimization in end-stage renal disease. The analysis found that patients had an average of 6.4 liters of ultrafiltrate removed over a mean duration of 78 hours, with stable hemodynamics even among those on vasopressor support.